SETD2 and chronic myelogenous leukemia, BCR-ABL1 positive: We found that inhibition of proteasome‐mediated degradation was sufficient to re‐express a (hyper‐ubiquitinated) SETD2 protein and to restore H3K36me3, indicating that in the majority of advanced‐phase CML patients, a functional SETD2 protein is regularly translated, but undergoes aberrant turnover.